Advice

following a full submission:

capecitabine (Xeloda®) is accepted for use within NHS Scotland.

Indication under review: The adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer in combination with oxaliplatin.

At 55 months, disease free survival was significantly increased for capecitabine plus oxaliplatin-treated patients compared with a recognised regimen containing a fluoropyramidine in the adjuvant treatment of patients with completely resected stage III (Dukes' C) colon cancer.

Download detailed advice132KB (PDF)

Download

Medicine details

Medicine name:
capecitabine (Xeloda)
SMC ID:
716/11
Indication:
In combination with oxaliplatin for the adjuvant treatment of patients following surgery of stage III (Dukes' stage C) colon cancer.
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published
08 August 2011